We also queried type 2 diabetes signatures and found PharmOmics was able to predict PPAR gamma agonist drugs (79% AUROC, p = 0.04, Figure 3H), but not sulfonylurea drugs that act on the pancreatic islets to enhance insulin release (prediction ranks in Table S2), due to a paucity of drug signatures in islets. Finally, we queried hyperuricemia signatures and network-based repositioning obtained 90% AUROC (p = 0.009, Figure 3I, prediction ranks in Table S3) for detecting antihyperuricemia drugs. This evidence concerns the gene INS and hyperuricemia.